Industry Strength Score
68/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
VYNE THERAPEUTICS INC (VYNE) Stock Price & Overview
NASDAQ:VYNE • US92941V3087
Current stock price
0.6412 USD
+0 (+0.71%)
At close:
0.6399 USD
0 (-0.2%)
After Hours:
The current stock price of VYNE is 0.6412 USD. Today VYNE is up by 0.71%. In the past month the price increased by 6.69%. In the past year, price decreased by -53.2%.
VYNE Key Statistics
52-Week Range0.2805 - 1.96
Current VYNE stock price positioned within its 52-week range.
1-Month Range0.5921 - 0.6495
Current VYNE stock price positioned within its 1-month range.
- Market Cap
- 21.365M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.61
- Dividend Yield
- N/A
VYNE Stock Performance
Today
+0.71%
1 Week
-0.60%
1 Month
+6.69%
3 Months
+13.27%
Longer-term
6 Months +80.26%
1 Year -53.20%
2 Years -74.76%
3 Years -89.81%
5 Years -99.10%
10 Years N/A
VYNE Stock Chart
VYNE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to VYNE. When comparing the yearly performance of all stocks, VYNE is a bad performer in the overall market: 86.06% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
VYNE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VYNE. While VYNE has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
VYNE Earnings
On February 27, 2026 VYNE reported an EPS of -0.11 and a revenue of 130.00K. The company beat EPS expectations (38.5% surprise) and missed revenue expectations (-36.27% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateFeb 27, 2026
PeriodQ4 / 2025
EPS Reported-$0.11
Revenue Reported130K
EPS Surprise 38.50%
Revenue Surprise -36.27%
VYNE Forecast & Estimates
10 analysts have analysed VYNE and the average price target is 3.32 USD. This implies a price increase of 417% is expected in the next year compared to the current price of 0.6412.
For the next year, analysts expect an EPS growth of -52.27% and a revenue growth 16.67% for VYNE
Analysts
Analysts78
Price Target3.32 (417.78%)
EPS Next Y-52.27%
Revenue Next Year16.67%
VYNE Financial Highlights
Over the last trailing twelve months VYNE reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 34.8% compared to the year before.
Income Statements
Revenue(TTM)570.00K
Net Income(TTM)-26.48M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.81% | ||
| ROE | -95.38% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%59.67%
Sales Q2Q%54.76%
EPS 1Y (TTM)34.8%
Revenue 1Y (TTM)13.77%
VYNE Ownership
Ownership
Inst Owners26.79%
Shares33.32M
Float31.78M
Ins Owners1.27%
Short Float %0.32%
Short Ratio0.46
VYNE Industry Overview
VYNE operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
47%
Outperformed 47% of sub-industries
3 Month Rank
55%
Outperformed 55% of sub-industries
6 Month Rank
41%
Outperformed 41% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 5.2%
- New Lows
- 3%
- Average ROE
- 51.3%
- Average Profit Margin
- 27.9%
- Average Operating Margin
- 37.7%
- Average P/E
- 25.5
- Average Fwd P/E
- 17.7
- Average Debt/Equity
- 1.2
VYNE Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.63 | 910.173B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 547.212B | ||
| MRK | MERCK & CO. INC. | 11.43 | 277.022B | ||
| PFE | PFIZER INC | 8.81 | 149.775B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 118.87B | ||
| ZTS | ZOETIS INC | 16.14 | 48.007B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.541B | ||
| VTRS | VIATRIS INC | 6.03 | 17.513B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.39 | 11.241B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.564B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.809B | ||
| CORT | CORCEPT THERAPEUTICS INC | 35.54 | 5.47B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VYNE
Company Profile
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 10 full-time employees. The company went IPO on 2018-01-25. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Company Info
IPO: 2018-01-25
VYNE THERAPEUTICS INC
685 Route 202/206 N., Suite 301
Bridgewater NEW JERSEY 08807 US
CEO: David Domzalski
Employees: 10
Phone: 18668207754
VYNE THERAPEUTICS INC / VYNE FAQ
What does VYNE do?
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 10 full-time employees. The company went IPO on 2018-01-25. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Can you provide the latest stock price for VYNE THERAPEUTICS INC?
The current stock price of VYNE is 0.6412 USD. The price increased by 0.71% in the last trading session.
Does VYNE stock pay dividends?
VYNE does not pay a dividend.
How is the ChartMill rating for VYNE THERAPEUTICS INC?
VYNE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is VYNE THERAPEUTICS INC (VYNE) expected to grow?
The Revenue of VYNE THERAPEUTICS INC (VYNE) is expected to grow by 16.67% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for VYNE THERAPEUTICS INC?
VYNE THERAPEUTICS INC (VYNE) has a market capitalization of 21.36M USD. This makes VYNE a Nano Cap stock.